Rebeccamycin analogues bearing amine substituents or other groups on the sugar moiety

被引:22
作者
Anizon, F
Moreau, P
Sancelme, M
Laine, W
Bailly, C
Prudhomme, M [1 ]
机构
[1] Univ Clermont Ferrand, Synth & Etud Syst Interet Biol, UMR 6504, CNRS, F-63177 Aubiere, France
[2] INSERM, U524, F-59045 Lille, France
[3] IRCL, Ctr Oscar Lambret, Lab Pharmacol Antitumorale, F-59045 Lille, France
关键词
D O I
10.1016/S0968-0896(03)00343-2
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In the course of structure-activity relationship studies on rebeccamycin analogues, a series of compounds bearing an amino function on the sugar moiety were synthesized with the aim of improving the solubility and interaction with the macromolecular target(s). The syntheses of amino derivatives and the corresponding chloro, iodo and azido intermediates are described. Their interaction with DNA and effects on human DNA topoisomerases I and II were investigated. Their antimicrobial activities against two Gram-positive bacteria, Bacillus cereus and Streptomyces chartreusis, a Gram-negative bacterium Escherichia coli and a yeast Candida albicans were also determined. 6'-Amino compound 7 and 6'-N-methylamino 14 very efficiently inhibit the growth of E. coli. The introduction of an amino group at the 6'-position strongly enhances the capacity of the drugs to interact with DNA but almost abolishes their poisoning effect on topoisomerase I. Unlike the vast majority of rebeccamycin analogues previously studied, the newly designed compounds do not stimulate DNA cleavage by topoisomerase I. The enhanced capacity of the 6'-amino glycosyl rebeccamycin derivatives to bind to DNA likely account for the improved biological profiles. DNA and topoisomerase I represent two independent targets which can both be used for the development of antitumor rebeccamycin derivatives. (C) 2003 Elsevier Ltd All rights reserved.
引用
收藏
页码:3709 / 3722
页数:14
相关论文
共 32 条
[1]  
AKINAGA S, 1991, CANCER RES, V51, P4888
[2]   Syntheses, biochemical and biological evaluation of staurosporine analogues from the microbial metabolite rebeccamycin [J].
Anizon, F ;
Moreau, P ;
Sancelme, M ;
Voldoire, A ;
Prudhomme, M ;
Ollier, M ;
Severe, D ;
Riou, JF ;
Bailly, C ;
Fabbro, D ;
Meyer, T ;
Aubertin, AM .
BIOORGANIC & MEDICINAL CHEMISTRY, 1998, 6 (09) :1597-1604
[3]   Recognition of specific sequences in DNA by a topoisomerase I inhibitor derived from the antitumor drug rebeccamycin [J].
Bailly, C ;
Colson, P ;
Houssier, C ;
Rodrigues-Pereira, E ;
Prudhomme, M ;
Waring, MJ .
MOLECULAR PHARMACOLOGY, 1998, 53 (01) :77-87
[4]   Enhanced binding to DNA and topoisomerase I inhibition by an analog of the antitumor antibiotic rebeccamycin containing an amino sugar residue [J].
Bailly, C ;
Qu, XG ;
Anizon, F ;
Prudhomme, M ;
Riou, JF ;
Chaires, JB .
MOLECULAR PHARMACOLOGY, 1999, 55 (02) :377-385
[5]  
Bailly C, 1999, CANCER RES, V59, P2853
[6]   DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin [J].
Bailly, C ;
Riou, JF ;
Colson, P ;
Houssier, C ;
RodriguesPereira, E ;
Prudhomme, M .
BIOCHEMISTRY, 1997, 36 (13) :3917-3929
[7]   DNA sequence recognition by the indolocarbazole antitumor antibiotic AT2433-B1 and its diastereoisomer [J].
Carrasco, C ;
Facompré, M ;
Chisholm, JD ;
Van Vranken, DL ;
Wilson, WD ;
Bailly, C .
NUCLEIC ACIDS RESEARCH, 2002, 30 (08) :1774-1781
[8]   TOTAL ASYMMETRIC SYNTHESES OF 1,5-DIDEOXY-1,5-IMINOOCTITOLS AND 1,2,6,7,8-PENTAHYDROXYINDOLIZIDINES [J].
CHEN, YW ;
VOGEL, P .
JOURNAL OF ORGANIC CHEMISTRY, 1994, 59 (09) :2487-2496
[9]  
DOWLATI A, 1999, P AN M AM SOC CLIN, V18, pA181
[10]   DNA binding and topoisomerase I poisoning activities of novel disaccharide indolocarbazoles [J].
Facompre, M ;
Carrasco, C ;
Colson, P ;
Houssier, C ;
Chisholm, JD ;
Van Vranken, DL ;
Bailly, C .
MOLECULAR PHARMACOLOGY, 2002, 62 (05) :1215-1227